• Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

    Hello everyone, I’m Xiaosheng Liu , a graduate student from Professor Taisheng Li’s team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I’m delighted to participate in this year’s…

  • Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

    Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya’s HIV Immunology…

  • Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

    Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring…

  • Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

    The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li’s team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li ‘s team, based on the latest findings from…

  • Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

    Editor’s Note: Over the years, significant progress has been made in the prevention and treatment of HIV/AIDS and co-infections. Society has provided the best medications and professional knowledge to combat HIV infections, making substantial contributions to those affected. From June 8th to 10th, 2023, the Asia-Pacific AIDS and Co-Infections Conference (APACC 2023) was held in…

  • Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

    Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to…

  • Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

    Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT…

  • Dr. Hongzhou Lu: Focus on the Aging of HIV/AIDS Patients, Intrinsic Capacity Assessment is Imperative!

    Editor’s Note: In recent years, with the effectiveness of antiretroviral therapy (ART) in suppressing HIV replication, the life expectancy of HIV-infected individuals has significantly increased. At the same time, the trend of aging among HIV/AIDS patients has gradually become a research hotspot in the field. From June 8th to 10th, 2023, the Asia Pacific AIDS…